{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-196040","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.210243+00:00","generated_at":"2026-05-31T11:42:16.514616+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Soleno reports Q2 2024 net loss of $21.9M; NDA for DCCR in PWS submitted to FDA","bullets":["NDA for Diazoxide Choline Extended-Release (DCCR) for Prader-Willi Syndrome with hyperphagia submitted to FDA.","Cash, cash equivalents and marketable securities of $294.6M as of June 30, 2024.","Net loss of $21.9M ($0.57 per share) for Q2 2024 vs. $8.5M ($0.81 per share) in Q2 2023.","R&D expense $12.3M (Q2 2024) up from $5.1M (Q2 2023) due to NDA submission and launch prep.","Closed $158.7M public offering of 3.45M shares at $46.00 each; BT designation for DCCR granted."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-196040","json":"https://secwatch.observer/filing/0001193125-24-196040.json","markdown":"https://secwatch.observer/filing/0001193125-24-196040.md","text":"https://secwatch.observer/filing/0001193125-24-196040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312524196040/0001193125-24-196040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312524196040/d892011d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:42:16.514616+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}